The Food and Drug Administration (FDA) has approved the preventive use of lenacapavir, marketed as Yeztugo. An injectable medication that has demonstrated greater than 99.9 percent efficacy in preventing HIV.
The drug is administered twice a year and has far outperformed previous treatments such as the daily pill Truvada. “Today is a historic day. This is the best opportunity in 44 years of HIV prevention.” Said Mitchell Warren, director of the AVAC organization.
Clinical trials revealed overwhelming results: among gay, bisexual, and transgender men who participated in the study. Yeztugo reduced new infections by 89 percent compared to the group that used daily pills.
In a second study, conducted with cisgender women in sub-Saharan Africa, none contracted HIV after receiving the injection. This new class of antiretrovirals works by blocking the replication of the virus within immune cells.
However, access could be limited by the high cost of treatment, which could reach $25,000 annually in the US.
Activists and experts fear that the price and barriers to medical coverage will prevent people from realizing its potential. “This really has the potential to end HIV transmission,” said Greg Millett, director of public policy at amfAR (American Foundation for AIDS Research).
With information from Instagram and rtve.es
- Cuba Reiterates Commitment to Population Protection Policies - 11 de July de 2025
- The Cristal Festival Returns to Holguin - 11 de July de 2025
- Parliament Publishes Corrected Versions of Bills - 11 de July de 2025